Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2025-03-11 Earnings Release
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the quarter ended December 31, 2024. It also notes that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3764 characters, which is relatively short and consistent with a report announcing an earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). However, since this is a Form 8-K furnishing a press release announcing quarterly results, it is effectively an Earnings Release filing. Therefore, the correct classification is ER with high confidence.
2025-03-11 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 19, 2025, by Werewolf Therapeutics, Inc. The content focuses on the departure of a director (Derek DiRocco) and the appointment of a new director (Anil Singhal) to the Board of Directors. It details the director's background, compensation, and committee appointment. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the correct classification is MANG with high confidence.
2025-02-24 English
4
Director's Dealing
2025-02-21 English
3
Director's Dealing
2025-02-21 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
4
Director's Dealing
2025-01-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.